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the HC2 assay versus cytology (84.5 vs. 69.7%; p  ! 0.0001) but 
a lower specificity (49.90 vs. 88.78%; p  ! 0.0001).  Conclusion: 
The combination of both methods seems to be useful in im-
proving detection of cervical lesions. 
 Copyright © 2012 S. Karger AG, Basel 
 Background 
 Cervical cancer is the second most common cancer in 
women worldwide  [1] , although its incidence has fallen 
by 50% or more in developed countries since the intro-
duction of Pap smear screening. However, a single cervi-
cal cytology test is insensitive for the detection of pre-
cancer and cancer of the cervix  [2] . Human papilloma-
virus (HPV) infection is very common in young women 
after the onset of sexual activity and, when it persists, the 
viral oncoproteins can disrupt cell-cycle controls, result-
ing in cervical intraepitheal neoplasia (CIN). In their 
mildest appearance, CIN1, these lesions are generally no 
more than manifestations of HPV infection, but at their 
most severe, CIN3, the risk of progression to invasive 
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 Abstract 
 Objectives: Robust evidence now supports human papillo-
mavirus (HPV) testing as a more effective option to screen-
ing and as more sensitive than cytology in detecting high-
grade cervical intraepithelial neoplasia . Our goal was to an-
alyze the performance of the Hybrid Capture II (HC2) assay 
for high-risk HPV (hrHPV) in women undergoing gynecolog-
ical examination at a public health hospital as part of the 
evaluation of HPV screening as an alternative or comple-
ment to cytology.  Study Design: This analysis is a subset of 
a cross-sectional study carried out at a large public hospital 
serving a predominantly low-resource population. A total of 
705 women were enrolled; the sensitivity and specificity of 
each test were estimated and compared.  Results: The analy-
sis identified 272 hrHPV-positive women (mean age 36.3 
years) and 433 hrHPV-negative women (mean age 41.2 years). 
HPV testing showed a significantly increased sensitivity of 
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cancer is higher. Fortunately, this transition usually 
takes years or decades, allowing for the opportunity to 
detect the cancer by cytology  [3] . A persistent infection 
with high-risk (hr)HPVs is the key event in the develop-
ment of cervical cancer and its precursor lesions; conse-
quently, the efficacy of cervical cancer screening can be 
improved by HPV testing. Substantial evidence now 
shows that HPV testing is more sensitive than cytology 
in detecting high-grade CIN, and some randomized 
controlled trials have demonstrated that it can detect 
persistent – and therefore clinically relevant – neoplasia 
earlier than cytology can  [4] . However, HPV testing is 
less specific than cytology, most likely because of the 
substantial number of HPV-positive women who harbor 
transient infections that clear spontaneously and do not 
cause high-grade lesions. 
 One HPV test, the Hybrid Capture 2 (HC2; Digene 
Corporation, currently QIAGEN, Gaithersburg, Md., 
USA) has been approved by the US Food and Drug Ad-
ministration (FDA) for use in cervical cancer screening 
for the triage of equivocal cytology and atypical squa-
mous cells of undetermined significance (ASCUS), and 
as a screening adjunct to cytology in women older than 
30 years  [5] . Given the evidence favoring the use of a com-
bination of cytology and HPV testing, we sought to in-
vestigate different cervical cancer screening strategies to 
ascertain the presence of cervical HPV-induced lesions, 
such as HPV testing, conventional Pap smear cytology 
and colposcopy, in the Hospital das Clínicas, School of 
Medicine of São Paulo State University, a reference public 
health hospital in Brazil. The objective was not to verify 
the possibility of introducing HC2 as an alternative meth-
od for screening a large general population, but to eval-
uate it as a methodological option for optimizing the 
screening of women undergoing gynecological examina-
tion for a variety of clinical reasons.
 Materials and Methods 
 Study Population 
 Between August 2008 and July 2009, 705 women were referred 
for a gynecology examination for different reasons (e.g., previous 
abnormal Pap test, follow-up of a treated cervical lesion). Eligibil-
ity requirements for participation in the study were as follows: age 
17–81 years and not currently pregnant. Women with chronic im-
mune suppression and those who were undergoing treatment for 
a CIN were evaluated in different groups. All women were invited 
to participate in the study and were enroled if they provided writ-
ten informed consent. The study was approved by the University 
of Sao Paulo ethics committee.
 Clinical Examinations 
 At the first visit, cytological samples were taken immediately 
after an HPV DNA test. For the conventional cytological test, an 
Ayre’s spatula was used to collect cells from the transformation 
zone, and a cytobrush was used to collect cells from the endocer-
vical canal. A cervical specimen for HPV DNA testing was taken 
by rotating a Dacron-tipped swab in the endocervical canal and 
swabbing it on the ectocervical epithelium. The swab was then 
placed in a specially prepared specimen transport medium (Di-
gene Corp.). 
 All women underwent colposcopy at the first visit, which was 
performed by members of a team of gynecologists with extensive 
training. Colposcopically guided biopsies of the worst visible le-
sions were obtained. Women with histological diagnoses of 
CIN2–3 were referred for loop electrosurgical excision proce-
dures. Women with invasive cancer were referred to a gyneco-
logic oncologist for appropriate staging and treatment. When 
the detected lesion did not correlate with cytological results, di-
agnostic loop electrosurgical excision procedures were per-
formed.
 Cytological and Histological Evaluation 
 For conventional cytology, a thin-layer slide was stained with 
Papanicolaou stain, screened by a cytotechnologist and reviewed 
by pathologists at the Hospital das Clínicas Medical Center (who 
had no knowledge of the other laboratory or clinical data). Cel-
lular changes were classified according to the Bethesda system. 
Biopsy specimen slides were reviewed by a pathologist with no 
knowledge of other clinical or laboratory data. 
 HPV DNA Testing 
 HPV testing was done using HC2 (Digene Corp.) with only the 
high-risk group of probes. These probes are designed to detect 
HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68. These 
tests were done according to the manufacturer’s instructions and 
results given as the ratio of the relative light units, which was con-
sidered positive when a relative light unit was greater than 1.0. 
Before initiating the study, the laboratory had completed the man-
ufacturer’s proficiency test and obtained very similar results on 
test samples. The HC2 manufacturer had no involvement in this 
study, and all supplies and reagents were purchased at the regular 
cost.
 Statistical Analysis 
 Sensitivity, specificity and positive and negative predictive 
values were calculated, generating 2  ! 2 tables, cross-classifying 
screening results and biopsy results. All estimates were calculated 
using biopsy-proven CIN2+ and CIN3+ as endpoints. The relative 
sensitivity of HPV testing using HC2 versus conventional cytol-
ogy was calculated as the ratio of detection rates of CIN2+ in the 
HPV-positive and HPV-negative groups, and we analyzed women 
according to age groups (15–20, 21–25, 26–29 and 30 years or old-
er). Because the prevalence of HPV infection is higher in younger 
women, our strategy was to compare relative sensitivity in each 
age group. Significance was defined as p  ! 0.05. Comparisons be-
tween proportions were made with the   2 test, and 95% confi-
dence intervals (CIs) for corrected estimates were calculated with 
the use of bootstrap resampling in which the sampling fractions 
were considered fixed. All analyses were conducted using SPSS 
software (version 15.0, SPSS Inc., Chicago, Ill., USA).
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 Results 
 A total of 705 women were recruited. They were divided 
into 2 large groups: HPV-positive (n = 272) and HPV-neg-
ative (n = 432). In the HPV-positive group, the median age 
was 36.3 versus 41.2 years in the negative group; 38.6% of 
the women had oncogenic HPV types, detected by HC2. 
Screening with the Pap test identified 168 (61.8%) women 
with cytological abnormalities in the HPV-positive group. 
The HPV-negative group had 44 (10.2%) abnormal smears. 
Both groups were divided into 4 prespecified age groups: 
17–20, 21–25, 25–29 and older than 30 years ( table  1 ). 
Women aged 30 years or more had a higher prevalence of 
oncogenic HPV than younger women (25 vs. 13.6%, re-
spectively), but were more likely to have normal cytological 
results (36 vs. 15%). Women with more severe cytological 
diagnoses were more likely to have a positive HC2 test than 
women with less severe cytological lesions.
 Histopathological results were available for 239 wom-
en who underwent colposcopically guided biopsy.  Table 2 
summarizes the results.
 Overall, testing with the HC2 test resulted in a signif-
icantly increased sensitivity when compared to the cyto-
logical method (84.5 vs. 69.7; p  ! 0.0001; CI 95%), but it 
was less specific (49.90 vs. 88.78%; p  ! 0.0001; CI 95%). 
We also identified more CIN2+ and CIN3+ in women 
aged 30 years or older than in the rest of the other groups. 
Sensitivity and specificity did not differ significantly be-
tween cytology and HC2 testing in the 15–29-year age 
group ( table 3 ).
 The combination of Pap smear and HPV DNA testing 
resulted in a sensitivity of 90.91% and a specificity of 48.04% 
for CIN2+ and CIN3+, indicating that using the two simul-
taneously improved sensitivity but not specificity.
 Discussion 
 Our results agree with those of previous reports that 
have demonstrated the efficiency of molecular tests in 
recognizing HPV infection and its correlated lesions. 
HC2 was clearly superior to cytology in screening women 
with HPV-induced lesions, with a significantly higher 
Table 1.  Distribution of HC2-positive test results for cytological results and age
Cytological results Patient ages distributed by intervals
15–20 years 21–25 years 26–29 years ≥ 30 years
HC2+ HC2– HC2+ HC2– HC2+ HC2– HC2+ HC2–
HSIL 1 – 2 – 7 1 40 6
LSIL 2 3 12 2 19 – 56 11
ASCUS – – – 4 3 2 14 15
AGC – – – – 2 – 4 –
AIS – – – – – – 1 –
Invasive cancer – – – – – – 1 –
Negative 8 11 15 39 17 34 68 303
Table 2.  Distribution of HC2-positive test results with histolog-
ical findings for 239 biopsies, diagnoses and age
Histological 
results
15–20 years 21–25 years 26–29 years ≥ 30 years
HC2+ HC2– HC+ HC2– HC2+ HC2– HC2+ HC2–
Negative 5 9 11 9 15 6 34 73
CIN1 1 – 6 1 7 – 16 2
CIN2 1 – – – 2 – 8 1
CIN3 1 – – – 3 1 12 1
VAIN 1 – – – – 2 – 2 –
VAIN 2 – – – – – – – 2
VAIN 3 – – – – 2 – 1 –
VIN 2–3 – – 2 – – – 1 1
MIC – – – – – – 1 –
Table 3.  Distribution of sensitivity and specificity of HC2 by age 
as compared with cytological (HSIL endpoint) results and age
Endpoint CIN2–3 Sensitivity Specificity
15–20 years 100%, p = 0.26 61%, p = 0.26
21–25 years 100%, p = 0.5 56%, p = 0.5
26–29 years 83%, p = 0.7 33%, p = 0.7
≥30 years 91%, p < 0.0001 70%, p < 0.0001
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sensitivity. The introduction of a molecular method into 
the hospital routine is also important for validating a new 
screening paradigm in the context of cervical carcino-
genesis  [2] .
 The recognition of the strong causal relationship be-
tween persistent infection of the genital tract with hrHPV 
types and the occurrence of cervical cancer has resulted 
in the development of a number of DNA and RNA detec-
tion systems for screening, to complement the limitations 
of cytology  [3] . In the USA, for example, HPV testing 
with cytology is approved for primary screening of wom-
en aged 30 years and older.
 Several studies based on double testing to screen for 
cervical lesions have shown that HPV testing has greater 
sensitivity than cytology but lower specificity in detect-
ing high-grade CIN  [6] . We also observed that HPV test-
ing has a higher sensitivity but lower specificity. Recent 
work, assessing absolute cross-sectional accuracy, found 
that the overall sensitivity of HC2 as a primary screening 
tool for detecting underlying high-grade CIN is 89.7% 
(range 50–100%) and that the pooled specificity of HC2, 
excluding high-grade cervical precancer, is 88.2% (range 
61–95%)  [3] . Furthermore, HC2 sensitivity has been con-
sistently high in 8 studies conducted in Europe and North 
America, but in developing countries such as Brazil, Zim-
babwe and South Africa, the sensitivity for HC2 is lower 
(83, 81, and 88%). 
 Several factors may influence this lower sensitivity, 
such as sample contamination by acetic acid or Lugol’s io-
dine or deterioration of the sample because of exposure to 
high environmental temperatures. The HC2 protocol 
notes that HC2 samples should be collected before other 
procedures. The lack of inclusion of other oncogenic HPV 
types in the HC2 probe cocktail is another potential expla-
nation for the lower sensitivity of the HC2 assay for some 
series, but this assumption is debatable  [3] . On the other 
hand, the pooled specificity of HC2 can be 6% lower than 
that of cytology, but the combination of cytology with 
HC2 yields higher values than cytology alone (46 vs. 35%); 
adding Pap smears to the HC2 test along with considering 
ASCUS or worse as a positive cytological result also in-
creases sensitivity by 6 and 4%, with CIN2 and CIN3 as 
endpoints, respectively. As a consequence, the specificity 
decreases by 5 and 7%. Accordingly, the most useful role 
for cytology may be its application, in women whose pri-
mary screen yielded positive results for HPV DNA, to 
avoid referral and overtreatment of those women with 
minimal or undetectable cytological abnormalities  [3] .
 Cross-reactivity may play a role in HC2 specificity. 
Previous studies have suggested that HC2 may cross-re-
act with HPV types either not associated with, or having 
undetermined associations with cancer (nononcogenic 
HPV), such as 6, 11, 26, 40, 42, 53, 66, 67, 71, 83 and 84. 
Castle et al.  [2] evaluated the effects of cross-reactivity on 
clinical performance by calculating sensitivity and spec-
ificity with and without cross-reactivity for the detection 
of high-grade cervical lesions. They tested 954 specimens 
using HC2 and HPV type-specific MY09/MY11 L1 con-
sensus primer PCR. According to their results, clinical 
sensitivity increased from 84.3 (without cross-reactivity) 
to 87.9%, specificity decreased from 89.6 to 88.1%, and 
referral rates increased from 11.7 to 13.2% for the detec-
tion of CIN2+. They also found that the clinical effect 
of cross-reactivity varied by cytological interpretation. 
Among women with normal cytology, cross-reactivity 
significantly improved the accuracy of identifying CIN2+. 
However, among women with equivocal or mildly abnor-
mal cytological alterations, cross-reactivity decreased the 
accuracy of HPV testing. They concluded that cross-re-
activity with nononcogenic HPV types had little effect on 
overall clinical performance. Alameda et al.  [7] compared 
the performance of HC2 and PCR using GP5+/6+ prim-
ers in 83 ASCUS cases and found 25.3% cross-reactivity 
with low-risk HPV. They also emphasized the impor-
tance of HPV typing, especially for HPV 16 infection. 
 Age is another important parameter for defining the 
target population to undergo screening  [8] . We found that 
women aged 30 years or older benefited more from HC2 
screening. Furthermore, the association between persis-
tence and high-grade cervical lesions is supposed to be 
more pronounced among women aged 25 years and older. 
Consequently, cervical screening works better in older 
women  [8] . HPV infections tend to be transient, and even 
the majority of abnormalities in young women, including 
CIN2 and CIN3, tend to regress spontaneously, a scenar-
io that may represent overtreatment and an increased risk 
of pregnancy-related morbidity  [6] . There is no benefit to 
screening the youngest women, but there is a significant 
risk reduction for women aged 30–37 years. Also, women 
aged 20–24 years contribute little to the incidence of cer-
vical cancer  [8] . 
 Regarding molecular tests, an HPV-positive status in 
young women can generate anxiety and psychological 
trauma when treating CIN that would never progress to 
cancer. For both situations, physicians can explain the im-
plications of a positive test at a young age and minimize 
the adverse effects of overtreatment. Vaccination before 
exposure to HPV also can reduce these problems  [9] .
 Because the screening goal is to avoid invasive cancer, 
it is indispensable to evaluate HPV testing performance. 
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Katki et al.  [10] studied the 5-year cumulative incidence 
of cervical cancer and CIN3+ in 331,818 women aged 30 
years and older enroled in cotesting. They found a 5-year 
cumulative incidence of cancer for HPV-negative women 
of 3.8 per 100,000 women, which was slightly higher than 
for the group undergoing both HPV testing and cytology 
(3.2 per 100,000 women). The rate for women with a neg-
ative Pap test result was 7.5 per 100,000 women. They also 
found that 73% of the women who were positive by HPV 
testing had no cytological abnormalities. Among these 
women, 35% had CIN3 or adenocarcinoma in situ, 29% 
had invasive carcinoma and 63% had invasive adenocar-
cinoma. The authors concluded that incorporating HPV 
testing with cytology also resulted in earlier identifica-
tion of women at high-risk of cervical cancer, especially 
adenocarcinoma, and that HPV testing without adjunc-
tive cytology might be sufficiently sensitive for primary 
screening. Dillner et al.  [8] reported similar results. They 
evaluated 24,295 women and calculated the long-term 
cumulative incidence of CIN3+. The cumulative inci-
dence rate of CIN3+ after 6 years for HPV-negative wom-
en was 0.27 versus 0.75% for women with negative cytol-
ogy. Women with negative cytology results but who were 
HPV-positive after 6 years had a cumulative incidence 
rate of up to 10%, while women who were HPV-negative 
but with cytological abnormalities had a 3% cumulative 
incidence rate of CIN3+.
 The major advantage of including HC2 in routine 
evaluations can be the increase in the length of screening 
intervals; these can be safely lengthened to 6 years among 
women with a negative HPV test  [6] . Women with normal 
cytology but a positive HPV test had a permanently in-
creasing cumulative incidence rate of CIN3+, eventually 
reaching 10% after 6 years. Women with an abnormal 
cytology and a negative HPV test had a cumulative inci-
dence rate for CIN3+ of 2.7%, and women with normal 
results for both tests had a very low risk of future CIN3+ 
(0.28%). 
 Women with an HPV-positive test result and who are 
cytology-negative are believed to be safely managed by 
repeating both tests after 1 year. This option allows for 
increasing sensitivity for high-grade lesions in compari-
son to conventional cytology alone, with only a small in-
crease in false-positives even in women younger than 35 
years  [11] . What is also advantageous is that the require-
ments for obtaining an adequate sample are less rigorous 
for HPV testing than for cytology  [11] .The overall relative 
sensitivity and specificity for self-taken samples is 74 and 
84%, respectively, suggesting that self-sampling for HPV 
testing is a valuable screening method for women who 
decline or who do not have the opportunity for an appro-
priate clinician-based screening, and is thus an impor-
tant way of improving population coverage of screening 
 [11–13] . 
 Cost estimates are an important issue for decision-
makers in public health systems. Screening alternatives 
rely on different levels and types of resources such as lab-
oratory infrastructure, staff mix and clinical visits. In 
2006, Goldhaber-Filbert and Goldie  [14] reported esti-
mated costs in 5 developing countries (India, Kenya, 
Peru, South Africa and Thailand) of cervical cytology 
and HPV testing. Cervical cytology is more labor-inten-
sive, requiring a broader range and quantity of labor in-
put with less reliance on equipment. HPV laboratories 
rely on automated processing, thus requiring less staff but 
requiring specific equipment. HPV tests are more expen-
sive than cytology, and the higher sensitivity increases 
referrals to colposcopy, which makes HPV testing more 
expensive at first sight. But if we consider the long term, 
HC2 may be economically viable once it can be safely 
used at up to 6-year intervals among women with a nega-
tive result on the HPV test, while a single cervical cytol-
ogy test is insensitive for the detection of precancer and 
cancer of the cervix.
 Because of significant data confirming that HPV test-
ing is substantially more sensitive than cytology at de-
tecting CIN2+, some authors have suggested its use as 
primary screening. However, HPV testing is somewhat 
less specific than cytology, primarily because of the de-
tection of transient infections that have not produced cy-
tological changes. These facts raise questions such as 
‘Should every HPV-positive woman be referred for col-
poscopy?’ If so, this strategy would become very costly. 
To answer these questions, Cuzick et al.  [3] proposed a 
possible algorithm for the use of HPV testing as primary 
screening. Women aged 25–64 years old should be in-
cluded. Women who test doubly negative could be re-
turned to routine screening and be recalled after 5 years. 
If HPV testing is positive, cytology should be performed. 
Only if cytology is positive should women be referred for 
colposcopy. Management of HPV-positive and cytology-
negative women presents a challenge, however. These 
women could be safely managed by repeating the testing 
with both cytology and HPV after 1 year.
 Finally, our study has some evident biases. First, all 
patients referred for the gynecological examination had 
had a previous abnormal Pap test, follow-up of a treated 
cervical lesion, etc., which resulted in 39% of patients 
being HPV-positive, obviously higher than the average 
population. Patients with former cervical lesion treat-
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ment and those with immunosuppression were evalu-
ated in different groups, to correct the bias. However, 
these groups were not statistically significant in the 
overall analysis. Another major bias was age. The FDA-
approved HC2 for women older than 30 years and 
screening programs for women under the age of 25 years 
are not effective. Brazil’s Health Ministry, however, rec-
ommends that the first Pap smears should be collected 
after the first sexual intercourse no matter a woman’s 
age, which sometimes obliges practitioners to use HC2 
for these young women very early. The recognition of the 
strong relationship between persistent infection with 
hrHPV types and the occurrence of cervical cancer has 
resulted in the development of a number of DNA and 
RNA detection systems for screening. Compared with 
cytology, HPV testing has a greater sensitivity  [6] , and 
the public health authorities could not ignore this im-
portant and strong evidence. In our study, HPV testing 
was more sensitive than cytology, and for women aged 
30 years or older, the specificity was quite acceptable 
(70%). Robust data published from around the world 
support the use of HPV testing for primary screening, 
and the combination with liquid-based cytology also of-
fers an increased specificity  [15] . Our study has demon-
strated that women in Brazil could benefit from this 
combination.
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